Table 4 Actionable Alterations identified in our cohort
Level of evidence based on OncoKB (12/20/2019) | Altered genes | Mutational type | No of patients | (%) | Related drugs |
|---|---|---|---|---|---|
| Â | Â | Â | 25 | 33.33 | Â |
1 | NTRK2 | Fusions | 1 | 1.33 | Entrectinib, Larotrectinib |
3 | ALK | Fusions | 1 | 1.33 | Crizotinib |
3 | BRAF | V600E | 1 | 1.33 | Dabrafenib, Dabrafenib + Trametinib, Vemurafenib + Cobimetinib, Encorafenib + Binimetinib, Encorafenib + Cetuximab, Encorafenib + Panitumumab, Trametinib, Vemurafenib |
3 | BRCA2 | Oncogenic Mutations | 1 | 1.33 | Niraparib, Olaparib, Rucaparib, Rucaparib |
3 | CDK12 | Oncogenic Mutations | 1 | 1.33 | Olaparib |
3 | EGFR | Exon 19 deletion, T790M | 5 | 6.67 | Afatinib, Dacomitinib, Erlotinib, Gefitinib, Osimertinib |
3 | ERBB2 | Amplification | 1 | 1.33 | Ado-Trastuzumab Emtansine, Capecitabine + Trastuzumab + Tucatinib, Lapatinib + Capecitabine, Lapatinib + Letrozole, Margetuximab + Chemotherapy, Neratinib + Capecitabine, Neratinib, Trastuzumab + Pertuzumab + Chemotherapy, Trastuzumab Deruxtecan, Trastuzumab, Trastuzumab + Chemotherapy, Lapatinib + Trastuzumab, Trastuzumab + Pertuzumab, Carboplatin-Taxol Regimen + Trastuzumab |
3 | PIK3CA | Oncogenic Mutations | 6 | 8.00 | Fulvestrant + Alpelisib |
3 | TSC1 | Oncogenic Mutations | 1 | 1.33 | Everolimus |
4 | AKT1 | E17K | 1 | 1.33 | AZD5363 |
4 | FGFR1 | Amplification | 3 | 4.00 | Debio1347, BGJ398, Erdafitinib |
4 | HRAS | Oncogenic Mutations | 3 | 4.00 | Tipifarnib |
4 | PTEN | Oncogenic Mutations | 5 | 6.67 | AZD8186, GSK2636771 |
4 | SF3B1 | Oncogenic Mutations | 2 | 2.67% | H3B-8800 |
4 | U2AF1 | Oncogenic Mutations | 1 | 1.33% | H3B-8800 |
Other potentially actionable gene | |||||
3 | BRCA1 | germline | 2 | 4.44% | Niraparib, Olaparib(PARPi) |
3 | BRCA2 | germline | 1 | 2.22% | Niraparib,Olaparib(PARPi) |
3 | ATM | germline | 1 | 2.22% | Olaparib (PARPi) |